Analysts Expect Endo International PLC (NASDAQ:ENDP) to Post $0.53 Earnings Per Share
Brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to report earnings of $0.53 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Endo International’s earnings. The lowest EPS estimate is $0.49 and the highest is $0.57. Endo International posted earnings of $0.71 per share in the same quarter last year, which would indicate a negative year over year growth rate of 25.4%. The firm is expected to issue its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Endo International will report full year earnings of $2.17 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.23. For the next year, analysts expect that the company will report earnings of $2.34 per share, with EPS estimates ranging from $1.71 to $3.13. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Monday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Endo International had a negative net margin of 19.98% and a negative return on equity of 129.30%. The firm had revenue of $699.71 million for the quarter, compared to analysts’ expectations of $694.60 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year.
NASDAQ:ENDP traded down $0.04 during mid-day trading on Friday, hitting $3.92. 167,274 shares of the company’s stock were exchanged, compared to its average volume of 9,744,917. The company has a market cap of $929.40 million, a PE ratio of 1.36 and a beta of 1.23. Endo International has a one year low of $1.97 and a one year high of $18.50. The business has a fifty day moving average price of $2.77 and a 200 day moving average price of $5.64.
In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $3.93, for a total transaction of $137,357.43. Following the completion of the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at approximately $582,854.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ENDP. Oregon Public Employees Retirement Fund increased its holdings in shares of Endo International by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares in the last quarter. Mason Street Advisors LLC increased its holdings in shares of Endo International by 3.4% during the 1st quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after purchasing an additional 2,134 shares in the last quarter. Piedmont Investment Advisors Inc. increased its holdings in shares of Endo International by 5.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock valued at $407,000 after purchasing an additional 2,795 shares in the last quarter. Comerica Bank increased its holdings in shares of Endo International by 2.1% during the 1st quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after purchasing an additional 4,001 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Endo International by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock valued at $1,287,000 after purchasing an additional 4,167 shares in the last quarter. 95.80% of the stock is owned by institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: Momentum Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.